Barrett’s oESophagus Trial 3 (BEST3)

• Research type

  Research Study

• Full title

  Barrett’s oESophagus Trial 3 (BEST3): Randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care.

• IRAS ID

  210292

• Contact name

  Rebecca Fitzgerald

• Contact email

  rcf29@mrc-cu.cam.ac.uk

• Sponsor organisation

  Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

• Duration of Study in the UK

  2 years, 8 months, 1 days

• Research summary

  We have developed a non-endoscopic diagnostic test for Barrett's oEsophagus (BE) which involves a device called the Cytosponge combined with molecular biomarker Trefoil Factor 3 (TFF3). The BEST3 study is now needed to:
  • Demonstrate that the invitation to the Cytosponge-TFF3 test leads to an increase in the number of patients diagnosed with BE compared to the usual clinical care pathway in primary care
  • Gain an in-depth understanding of the health economics of the Cytosponge -TFF3 test in patients on long-term treatment with acid suppressants as as well as the economics for the projected reduction of cancer-related deaths.

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  16/EE/0546

• Date of REC Opinion

  25 Jan 2017

• REC opinion

  Further Information Favourable Opinion